Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.68 |
| ▸ | NPC1 | O15118 | 12/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.62 |
| ▸ | HPGD | P15428 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769677 | 0.91 | RAB9A (0.65) | RAB9ANPC1POLBKDM4EHPGD | |
| SCHEMBL769336 | 0.89 | RAB9A (0.63) | RAB9ANPC1POLBKDM4EHPGD | |
| SCHEMBL770450 | 0.89 | MAPT (0.65) | RAB9ANPC1POLBKDM4EHPGD | |
| SCHEMBL770154 | 0.88 | RAB9A (0.64) | RAB9ANPC1POLBKDM4EHPGD | |
| SCHEMBL769761 | 0.88 | NPC1 (0.64) | RAB9ANPC1POLBKDM4EHPGD | |
| SCHEMBL770479 | 0.88 | RAB9A (0.64) | RAB9ANPC1POLBKDM4EHPGD | |
| SCHEMBL769479 | 0.88 | RAB9A (0.64) | RAB9ANPC1POLBKDM4EHPGD | |
| SCHEMBL770705 | 0.88 | RAB9A (0.64) | RAB9ANPC1POLBKDM4EHPGD | |
| SCHEMBL769843 | 0.88 | RAB9A (0.64) | RAB9ANPC1POLBKDM4EHPGD | |
| SCHEMBL769960 | 0.88 | RAB9A (0.61) | RAB9ANPC1POLBKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | claimed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | claimed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7977365-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7872037-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2011-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | ZC3HAV1, GZMB, GTF3C3 | RAB9A 3973/4885NPC1 337/4885POLB 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.